Acrivon Therapeutics, Inc. Common Stock (ACRV) Stock

Acrivon Therapeutics, Inc. Common Stock (ACRV) is a Healthcare stock trading at $2.21 (as of 2026-08-21), with a market capitalization of $94.59M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing oncology therapies by using a proteomics-based approach to identify patients whose tumors are predicted to be sensitive to specific medicines. It applies this platform to create drug-specific companion diagnostics and is advancing ACR-368 in a Phase 2 trial, with additional preclinical programs targeting DNA damage response and cell-cycle regulation pathways.

Valuation — source: SEC EDGAR (first-party)
Price$2.21
Market Cap$94.59M
Price / Book1.09
FCF Yield-133.7%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$7.00M
Net Margin-862.7%
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderRA CAPITAL MANAGEMENT, L.P. ($11.59M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOPeter Blume-Jensen
Employees75
CountryUS
IPO Date2022-11-15

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Polaryx Therapeutics, Inc. Common Stock (PLYX)
  • Biomea Fusion, Inc. (BMEA)
  • Fortress Biotech, Inc. (FBIO)
  • Aldeyra Therapeutics, Inc. (ALDX)
  • Rallybio Corporation (RLYB)
  • Gain Therapeutics, Inc. (GANX)
  • Adicet Bio, Inc. (ACET)
  • MAIA Biotechnology, Inc. (MAIA)
ACRV earnings history · ACRV institutional & insider holders · ACRV KPIs & operating metrics · ACRV financials · ACRV investor presentations & press releases · ACRV SEC filings · ACRV peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.